Publications by authors named "L Triggiani"
Purpose: Prostate cancer treatments paradigms are in continuous evolution, especially in the metastatic setting. In this context, the Genito-Urinary Group of Italian Association of Radiotherapy and Clinical Oncology aimed to create a consensus on radiation therapy indication in de novo metastatic hormone-sensitive prostate cancer both on primary tumor and metastatic sites.
Methods: A panel of experts, involved in clinical management of prostate cancer, through the estimate-talk-estimate method, developed a list of items and correspondent statements on the identified topic.
Metastasis-directed therapy (MDT) has been tested in clinical trials as a treatment option for oligorecurrent prostate cancer (PCa). However, there is an ongoing debate regarding the impact of using different imaging techniques interchangeably for defining lesions and guiding MDT within clinical trials. We retrospectively identified oligorecurrent PCa patients who had 5 or fewer nodal, bone, or visceral metastases detected by choline or prostate-specific membrane antigen (PSMA) PET/CT and who underwent MDT stereotactic body radiotherapy with or without systemic therapy in 8 tertiary-level cancer centers.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates how stereotactic body radiation therapy (SBRT) affects lymph-nodal prostate cancer oligometastases, focusing on the different treatment outcomes between pelvic and para-aortic lymph nodes.
- A total of 240 lymph-nodal oligometastases from 164 patients were analyzed, revealing a median progression-free survival (PFS) of 20 months for pelvic cases versus 11 months for para-aortic cases, although this difference wasn’t significant in further analyses.
- The findings indicate that while patients with para-aortic disease may have comparable PFS to those with pelvic disease, both groups demonstrate high local control rates, suggesting SBRT is beneficial for treating para-aortic metastases.
Background: Among its extragonadal effects, follicle-stimulating hormone (FSH) has an impact on body composition and bone metabolism. Since androgen deprivation therapy (ADT) has a profound impact on circulating FSH concentrations, this hormone could potentially be implicated in the changes of fat body mass (FBM), lean body mass (LBM), and bone fragility induced by ADT. The objective of this study is to correlate FSH serum levels with body composition parameters, bone mineral density (BMD), and bone turnover markers at baseline conditions and after 12 months of ADT.
View Article and Find Full Text PDF